Researcher: J&J/Pharmacyclics Drug Could Be a Game-Changer

XCSFDHG46767FHJHJF

tdp2664 InvestorPlace Take a bow, Johnson & Johnson (NYSE: JNJ ). It certainly appears the company knew what it was doing last week when it made a deal for a Pharmacyclics ‘ (NASDAQ: PCYC ) experimental cancer drug. The compound –